Arvinas Stock Price, News & Analysis

Arvinas, a clinical-stage biotechnology company, reported significant developments in its drug pipeline, specifically ARV-471, for treating ER+/HER2- metastatic breast cancer. The company initiated a Phase 3 trial for this monotherapy and presented Phase 2 data from the VERITAC trial. Arvinas gained FDA alignment for a Phase 3 trial combining ARV-471 with palbociclib, set to start in 2H 2023. Financially, Arvinas recorded revenue of $131.4 million for 2022, up from $53.6 million in 2021, largely due to the ARV-471 collaboration with Pfizer. However, the company also posted a net loss of $282.5 million and research expenses rose to $315 million.

Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, announced participation in three investor conferences. The events include the Guggenheim Oncology Conference on February 9, featuring a fireside chat with Chief Medical Officer Ron Peck and CFO Sean Cassidy. The SVB Leerink Global Healthcare Conference on February 16 will include Ron Peck and Randy Teel, Senior VP of Corporate Development. Finally, the Citi Oncology Leadership Summit on February 23 will feature Chief Scientific Officer Ian Taylor. Live audio webcasts will be available for each presentation on the company’s website.

Arvinas, a clinical-stage biotechnology company, will present an overview at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 1:30 p.m. PT in San Francisco. CEO John Houston will lead the presentation, focusing on the company's innovative approach to targeted protein degradation. Arvinas utilizes its proprietary PROTAC® Discovery Engine to develop therapies aimed at devastating diseases, including investigational programs for metastatic prostate and breast cancer. A live audio webcast of the presentation will be available online.

Arvinas, a clinical-stage biotechnology firm, announces the resignation of Brad Margus from its Board, with Everett Cunningham appointed as his replacement. Margus was a valued member of the Audit Committee, contributing significantly to Arvinas' development. Cunningham brings over 25 years of experience in pharmaceuticals, previously holding key roles at Exact Sciences and GE Healthcare. With expertise in commercialization and a strong background in medical services, Cunningham is expected to enhance Arvinas’ transition into late-stage development and improve patient outcomes.

ARV-471, a novel PROTAC® estrogen receptor degrader, exhibits promising activity in patients with advanced ER+/HER2- breast cancer, achieving a median progression-free survival of 3.7 months overall and 5.7 months in patients with ESR1 mutant tumors. A clinical benefit rate of 38% was recorded in a heavily pre-treated cohort. Initial results from the VERITAC trial support the initiation of two Phase 3 trials. The study emphasizes ARV-471's favorable tolerability profile and potential as a new standard of care, with plans to initiate pivotal trials in late 2022 and early 2023.

Arvinas, Inc. (Nasdaq: ARVN) reported its third-quarter financial results for 2022, highlighting significant progress in clinical trials and executive team enhancements. The company is set to initiate two Phase 3 trials of ARV-471 for metastatic breast cancer by the year's end. Financially, revenues climbed to $30.3 million from $9.3 million in Q3 2021, driven by the ARV-471 collaboration. However, the net loss rose to $66.2 million, up from $46.8 million year-over-year, primarily due to increased R&D and administrative expenses.

Arvinas, a clinical-stage biotechnology company, will present at two key conferences in November 2022. At the Society for Neuroscience Annual Meeting, Angela Cacace will showcase research on PROTAC^® molecules targeting neurodegenerative proteins on November 12. Additionally, Arvinas will participate in the Stifel Healthcare Conference with Ron Peck and Randy Teel engaging in a fireside chat on November 15. The company focuses on innovative therapies that degrade disease-causing proteins, currently advancing multiple clinical-stage programs, including treatments for prostate and breast cancer.

Arvinas, Inc. (Nasdaq: ARVN) announced the appointment of Paul McInulty as Senior Vice President of Regulatory Affairs, effective October 3, 2022. McInulty brings over 25 years of biopharmaceutical experience, having previously held key roles at Bristol Myers Squibb and Celgene Corporation. His expertise will support Arvinas' transition into a late-stage development company focused on targeted protein degradation therapies. With a robust pipeline, including investigational programs for metastatic prostate and breast cancer, Arvinas aims to leverage McInulty’s experience to enhance regulatory strategies and overall growth trajectory.